Core Viewpoint - AngioDynamics reported stronger-than-expected Q4 2025 sales and earnings, but the overall market reaction was negative due to ongoing losses and cautious guidance for the upcoming fiscal year [1][2][4]. Financial Performance - Q4 sales increased by 13% year-over-year, reaching $80.2 million, while gross profit margins declined by 160 basis points to 52.7% [4]. - Adjusted loss per share was $0.03, better than the forecasted loss of $0.12, and GAAP loss per share improved from $0.33 a year ago to $0.15 [4][5]. - For the full fiscal year 2025, AngioDynamics reported a loss of $0.83 per share under GAAP, with sales growth of only 8.1% [5]. Future Guidance - The company expects fiscal 2026 sales to be between $305 million and $310 million, which exceeds Wall Street forecasts [6]. - However, management warned of expected losses ranging from $0.25 to $0.35 per share, adjusted for one-time items, which is worse than the $0.23 per-share loss anticipated by analysts [6][7].